Temasek, its wholly-owned subsidiary True Light Capital, and HighLight Capital have invested around $210 million in Chinese drug discovery service provider VIVA Biotech Holdings, according to a company announcement on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
